BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Jee AS, Corte TJ. Current and Emerging Drug Therapies for Connective Tissue Disease-Interstitial Lung Disease (CTD-ILD). Drugs 2019;79:1511-28. [PMID: 31399860 DOI: 10.1007/s40265-019-01178-x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 8.5] [Reference Citation Analysis]
Number Citing Articles
1 Wang Y, Li L. Rituximab for connective tissue disease‐associated interstitial lung disease: A systematic review and meta‐analysis. Int J of Rheum Dis 2022. [DOI: 10.1111/1756-185x.14495] [Reference Citation Analysis]
2 Glenn LM, Troy LK, Corte TJ. Diagnosing interstitial lung disease by multidisciplinary discussion: A review. Front Med 2022;9. [DOI: 10.3389/fmed.2022.1017501] [Reference Citation Analysis]
3 Dias VL, Storrer KM. Prevalence of latent tuberculosis infection among patients with interstitial lung disease requiring immunosuppression. J Bras Pneumol 2022;48:e20210382. [PMID: 35352793 DOI: 10.36416/1806-3756/e20210382] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
4 De Zorzi E, Spagnolo P, Cocconcelli E, Balestro E, Iaccarino L, Gatto M, Benvenuti F, Bernardinello N, Doria A, Maher TM, Zanatta E. Thoracic Involvement in Systemic Autoimmune Rheumatic Diseases: Pathogenesis and Management. Clin Rev Allergy Immunol 2022. [PMID: 35303257 DOI: 10.1007/s12016-022-08926-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
5 Xue M, Zhang T, Lin R, Zeng Y, Cheng ZJ, Li N, Zheng P, Huang H, Zhang XD, Wang H, Sun B. Clinical utility of heparin‐binding protein as an acute‐phase inflammatory marker in interstitial lung disease. J Leukocyte Bio. [DOI: 10.1002/jlb.3ma1221-489r] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Drakopanagiotakis F, Günther A. Grundlagen der medikamentösen Therapie. Seltene Lungenerkrankungen 2022. [DOI: 10.1007/978-3-662-63651-0_5] [Reference Citation Analysis]
7 Deng L, Chen Y, Hu X, Zhou J, Zhang Y. Case Report: Successful Treatment of Refractory Interstitial Lung Disease With Cyclosporine A and Pirfenidone in a Child With SLE. Front Immunol 2021;12:708463. [PMID: 34671344 DOI: 10.3389/fimmu.2021.708463] [Reference Citation Analysis]
8 Samarelli AV, Tonelli R, Marchioni A, Bruzzi G, Gozzi F, Andrisani D, Castaniere I, Manicardi L, Moretti A, Tabbì L, Cerri S, Beghè B, Dominici M, Clini E. Fibrotic Idiopathic Interstitial Lung Disease: The Molecular and Cellular Key Players. Int J Mol Sci 2021;22:8952. [PMID: 34445658 DOI: 10.3390/ijms22168952] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
9 Shao S, Qu Z, Liang Y, Xu Y, Zhou D, Li D, Zhang Y, Yin S. Iguratimod decreases bleomycin-induced pulmonary fibrosis in association with inhibition of TNF-α in mice. Int Immunopharmacol 2021;99:107936. [PMID: 34284287 DOI: 10.1016/j.intimp.2021.107936] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
10 Li Y, Zhu W, He H, Garov YA, Bai L, Zhang L, Wang J, Wang J, Zhou X. Efficacy and Safety of Tripterygium Wilfordii Hook. F for Connective Tissue Disease-Associated Interstitial Lung Disease:A Systematic Review and Meta-Analysis. Front Pharmacol 2021;12:691031. [PMID: 34177599 DOI: 10.3389/fphar.2021.691031] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
11 Shao T, Shi X, Yang S, Zhang W, Li X, Shu J, Alqalyoobi S, Zeki AA, Leung PS, Shuai Z. Interstitial Lung Disease in Connective Tissue Disease: A Common Lesion With Heterogeneous Mechanisms and Treatment Considerations. Front Immunol 2021;12:684699. [PMID: 34163483 DOI: 10.3389/fimmu.2021.684699] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
12 Chen X, Wang F, Huang Z, Wu Y, Geng J, Wang Y. Clinical applications of mesenchymal stromal cell-based therapies for pulmonary diseases: An Update and Concise Review. Int J Med Sci 2021;18:2849-70. [PMID: 34220313 DOI: 10.7150/ijms.59218] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
13 Mann H, Vencovský J. Clinical Trials in Myositis: Where Do We Stand? Curr Treat Options in Rheum 2021;7:222-42. [DOI: 10.1007/s40674-021-00180-3] [Reference Citation Analysis]
14 Innabi A, Gomez-Manjarres D, Alzghoul BN, Chizinga M, Mehrad B, Patel DC. Cyclophosphamide for the treatment of Acute Exacerbation of Interstitial Lung Disease: A Review of the Literature. Sarcoidosis Vasc Diffuse Lung Dis 2021;38:e2021002. [PMID: 33867789 DOI: 10.36141/svdld.v38i1.11271] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
15 Seeliger B, Prasse A. Immunmodulation bei autoimmunen interstitiellen Lungenerkrankungen. Kompass Autoimmun 2021;3:2-9. [DOI: 10.1159/000514258] [Reference Citation Analysis]
16 Jee AS, Sheehy R, Hopkins P, Corte TJ, Grainge C, Troy LK, Symons K, Spencer LM, Reynolds PN, Chapman S, de Boer S, Reddy T, Holland AE, Chambers DC, Glaspole IN, Jo HE, Bleasel JF, Wrobel JP, Dowman L, Parker MJS, Wilsher ML, Goh NSL, Moodley Y, Keir GJ. Diagnosis and management of connective tissue disease-associated interstitial lung disease in Australia and New Zealand: A position statement from the Thoracic Society of Australia and New Zealand. Respirology 2021;26:23-51. [PMID: 33233015 DOI: 10.1111/resp.13977] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
17 Cereser L, Marchesini F, Di Poi E, Sacco S, De Marchi G, Linda A, Como G, Zuiani C, Girometti R. Structured report for chest high-resolution computed tomography in patients with connective tissue disease: Impact on the report quality as perceived by referring clinicians. Eur J Radiol 2020;131:109269. [PMID: 32949860 DOI: 10.1016/j.ejrad.2020.109269] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
18 Krause A, Kreuter M. Lungenmanifestationen rheumatischer Erkrankungen schon früh mitbedenken. Pneumo News 2020;12:33-42. [DOI: 10.1007/s15033-020-1895-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
19 Peng H, Wu X, Wen Y, Li C, Lin J, Li J, Xiong S, Zhong R, Liang H, Cheng B, Liu J, He J, Liang W. Association between systemic sclerosis and risk of lung cancer: results from a pool of cohort studies and Mendelian randomization analysis. Autoimmun Rev 2020;19:102633. [PMID: 32801043 DOI: 10.1016/j.autrev.2020.102633] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]